Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$240.71+0.94 (+0.39%)
Close on Nov 17, 2026Market cap $15.63BP/E 78.4Yield –
Jazz Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Jazz Pharmaceuticals's total assets was $12.00B at Sep 30, 2026. For fiscal 2025 it was $11.66B, down 2.9% from the year before. Over ten years it grew 13.3% a year on average. The highest annual figure on record is $12.30B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.66B | -2.9% |
| FY2024 | Dec 31, 2024 | $12.01B | +5.4% |
| FY2023 | Dec 31, 2023 | $11.39B | +5.2% |
| FY2022 | Dec 31, 2022 | $10.84B | -11.9% |
| FY2021 | Dec 31, 2021 | $12.30B | +88.2% |
| FY2020 | Dec 31, 2020 | $6.54B | +18.0% |
| FY2019 | Dec 31, 2019 | $5.54B | +6.4% |
| FY2018 | Dec 31, 2018 | $5.20B | +1.6% |
| FY2017 | Dec 31, 2017 | $5.12B | +6.7% |
| FY2016 | Dec 31, 2016 | $4.80B | +44.0% |
| FY2015 | Dec 31, 2015 | $3.33B | -0.2% |
| FY2014 | Dec 31, 2014 | $3.34B | +49.2% |
| FY2013 | Dec 31, 2013 | $2.24B | +13.8% |
| FY2012 | Dec 31, 2012 | $1.97B | +675.5% |
| FY2011 | Dec 31, 2011 | $253.57M | +86.8% |
| FY2010 | Dec 31, 2010 | $135.73M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $12.00B | +5.6% |
| Q2 FY2026 | Jun 30, 2026 | $11.08B | +1.2% |
| Q1 FY2026 | Mar 31, 2026 | $11.86B | +2.8% |
| Q4 FY2025 | Dec 31, 2025 | $11.66B | -2.9% |
| Q3 FY2025 | Sep 30, 2025 | $11.36B | -7.3% |
| Q2 FY2025 | Jun 30, 2025 | $10.94B | -3.7% |
| Q1 FY2025 | Mar 31, 2025 | $11.53B | +1.8% |
| Q4 FY2024 | Dec 31, 2024 | $12.01B | +5.4% |
| Q3 FY2024 | Sep 30, 2024 | $12.26B | +9.4% |
| Q2 FY2024 | Jun 30, 2024 | $11.36B | +0.9% |
| Q1 FY2024 | Mar 31, 2024 | $11.33B | +2.5% |
| Q4 FY2023 | Dec 31, 2023 | $11.39B | +5.2% |
| Q3 FY2023 | Sep 30, 2023 | $11.20B | +7.9% |
| Q2 FY2023 | Jun 30, 2023 | $11.26B | +0.5% |
| Q1 FY2023 | Mar 31, 2023 | $11.05B | -6.1% |
| Q4 FY2022 | Dec 31, 2022 | $10.84B | -11.9% |
| Q3 FY2022 | Sep 30, 2022 | $10.38B | -16.8% |
| Q2 FY2022 | Jun 30, 2022 | $11.20B | -15.2% |
| Q1 FY2022 | Mar 31, 2022 | $11.77B | +74.2% |
| Q4 FY2021 | Dec 31, 2021 | $12.30B | +88.2% |
| Q3 FY2021 | Sep 30, 2021 | $12.48B | +98.3% |
| Q2 FY2021 | Jun 30, 2021 | $13.21B | +117.8% |
| Q1 FY2021 | Mar 31, 2021 | $6.76B | +29.6% |
| Q4 FY2020 | Dec 31, 2020 | $6.54B | +18.0% |
| Q3 FY2020 | Sep 30, 2020 | $6.29B | +13.8% |
| Q2 FY2020 | Jun 30, 2020 | $6.07B | +10.5% |
| Q1 FY2020 | Mar 31, 2020 | $5.22B | -1.2% |
| Q4 FY2019 | Dec 31, 2019 | $5.54B | +6.4% |
| Q3 FY2019 | Sep 30, 2019 | $5.53B | +0.8% |
| Q2 FY2019 | Jun 30, 2019 | $5.49B | +2.6% |
| Q1 FY2019 | Mar 31, 2019 | $5.28B | -0.1% |
| Q4 FY2018 | Dec 31, 2018 | $5.20B | +1.6% |
| Q3 FY2018 | Sep 30, 2018 | $5.49B | +9.7% |
| Q2 FY2018 | Jun 30, 2018 | $5.35B | +11.3% |
| Q1 FY2018 | Mar 31, 2018 | $5.29B | +9.8% |
| Q4 FY2017 | Dec 31, 2017 | $5.12B | +6.7% |
| Q3 FY2017 | Sep 30, 2017 | $5.00B | – |
| Q2 FY2017 | Jun 30, 2017 | $4.80B | – |
| Q1 FY2017 | Mar 31, 2017 | $4.82B | – |
| Q4 FY2016 | Dec 31, 2016 | $4.80B | – |
See a number that looks wrong?